carboplatin + cisplatin + durvalumab + etoposide + olaparib

This is a multi-agent combination regimen consisting of five drugs with distinct mechanisms of action, used in oncology clinical trials and investigational settings. The components are: - **Carboplatin** and **cisplatin** are platinum-based alkylating agents that form DNA cross-links, inhibiting DNA synthesis and function, leading to apoptosis in rapidly dividing tumor cells. They have different toxicity profiles but can be combined to increase dose intensity while leveraging their non-overlapping toxicities[1][3][5][6]. - **Etoposide** is a topoisomerase II inhibitor that induces DNA strand breaks by preventing the re-ligation of double-stranded breaks created during normal DNA replication. - **Durvalumab** is a monoclonal antibody immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), enhancing anti-tumor immune responses. - **Olaparib** is an oral small molecule PARP (poly ADP ribose polymerase) inhibitor that impairs single-strand DNA repair, particularly effective in tumors with BRCA mutations or homologous recombination deficiency[7]. This combination targets cancer through direct cytotoxicity (DNA damage), inhibition of cell division, and stimulation of anti-tumor immunity. It may be explored for high-risk or refractory cancers where multiple mechanisms are needed for disease control.